drug
vorinostat
Marketedupdated 3mo agoby $MRK Merck & Co., Inc.
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying vorinostat
- phase2TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II
- phase2Vorinostat,Lenalinomide and Dexamethasone in Multiple Myeloma Refractory to Previous Lenalinomide Containing Regimens
- phase1Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
- phase2Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- phase2Study of Vorinostat (MK-0683) With Follicular Lymphoma (FL), Other Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL), or Mantle Cell Lymphoma (MCL) Participants (MK-0683-103)
- phase2Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer
- phase2Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC)
- phase3Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma
Patent cliff
source: FDA Orange Bookfirst barrier falls
Mar 11, 2027
202 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- Mar 18, 2028method-of-use (U-892)US 84503721.6y
- Mar 11, 2027compositionUS 7456219202d
- May 16, 2026formulationUS 8093295
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 5m ago
Found something off?
comments(0)
5-min edit window · permanent after that